Drug Guide
Oxycodone Hydrochloride
Classification
Therapeutic: Opioid analgesic
Pharmacological: Mu-opioid receptor agonist
FDA Approved Indications
- Moderate to severe pain management
Mechanism of Action
Binds to mu-opioid receptors in the central nervous system, altering the perception of and response to pain.
Dosage and Administration
Adult: Dose varies based on severity; typically 10-20 mg every 4-6 hours as needed, titrated to response.
Pediatric: Use is generally not recommended for children under 18 due to safety concerns.
Geriatric: Start at lower dose; monitor closely due to increased sensitivity and potential for adverse effects.
Renal Impairment: Adjust dose cautiously; renal function monitoring recommended.
Hepatic Impairment: Dose adjustment may be necessary; hepatic function should be evaluated.
Pharmacokinetics
Absorption: Well absorbed orally.
Distribution: Widely distributed in body tissues, crosses blood-brain barrier.
Metabolism: Primarily metabolized in the liver via CYP3A4 and CYP2D6 pathways.
Excretion: Excreted mainly in urine; metabolites may be detected in feces.
Half Life: Generally 3-4.5 hours for immediate-release; longer for extended-release formulations.
Contraindications
- History of hypersensitivity to oxycodone or other opioids
- Acute bronchial asthma in an unmonitored setting
Precautions
- Use with caution in respiratory depression, increased intracranial pressure, head injury, hepatic impairment, alcoholism, and in the elderly.
Adverse Reactions - Common
- Constipation (Common)
- Nausea (Common)
- Drowsiness (Common)
- Dizziness (Common)
Adverse Reactions - Serious
- Respiratory depression (Serious)
- Hypotension (Serious)
- Addiction, abuse, and misuse (Serious)
- Serotonin syndrome (when combined with serotonergic agents) (Serious)
Drug-Drug Interactions
- CNS depressants (e.g., benzodiazepines, alcohol)
- Other opioids
- MAO inhibitors
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Assess pain prior to and 1 hour after administration.
Diagnoses:
- Acute pain related to tissue injury, as evidenced by patient report
Implementation: Administer around the clock or as needed, monitor respiratory status, bowel function, and signs of misuse.
Evaluation: Effective pain control with minimal adverse effects.
Patient/Family Teaching
- Take medication exactly as prescribed.
- Do not exceed the recommended dose or frequency.
- Avoid alcohol and other CNS depressants.
- Report signs of respiratory depression, excessive sedation, or allergic reactions.
Special Considerations
Black Box Warnings:
- Addiction, abuse, and misuse potentially leading to overdose and death.
- Life-threatening respiratory depression.
Genetic Factors: Variability in CYP2D6 enzyme activity can affect metabolism and response.
Lab Test Interference: May falsely elevate alkaline phosphatase levels.
Overdose Management
Signs/Symptoms: Respiratory depression, extreme somnolence, muscle flaccidity, cold and clammy skin, pinpoint pupils, unresponsiveness.
Treatment: Administer naloxone promptly; ensure airway support, provide ventilatory assistance if needed, and monitor until full recovery.
Storage and Handling
Storage: Store at room temperature away from light and moisture.
Stability: Stable under recommended conditions for shelf life specified in the packaging.